NCT05767632: Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands) |
|
|
| Completed | 1 | 30 | RoW | Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose), Vesicare & Betmiga, Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test), Mirfenacin MR, Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose) | Genuine Research Center, Egypt, Hikma Pharma | Healthy | 07/22 | 10/22 | | |
